Acute Coronary Syndrome with Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event

Publication date: Available online 11 December 2019Source: Canadian Journal of CardiologyAuthor(s): Jennifer Cautela, Franck Rouby, Joe-Elie Salem, Joachim Alexandre, Ugo Scemama, Charles Dolladille, Ariel Cohen, Franck Paganelli, Stéphane Ederhy, Franck ThunyAbstractIsolated cases of acute coronary syndromes (ACSs) associated with immune checkpoint inhibitors (ICIs) have been described without the establishment of a formal cause-and-effect relationship between treatment and adverse event.First, we reported a case of ACS after the first administration of an ICI and with a fatal recurrence in another coronary area immediately after readministration. According to the guidelines, causality was considered as certain. Subsequently, the French pharmacovigilance database was queried and found four cases of ACS with coronary artery thrombosis. Causality was probable in these patients.These data suggest that ACS may be another life-threatening cardiac adverse event occurring with ICIs exposure.
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research